Evolent Health
EVH
215 hedge funds and large institutions have $482M invested in Evolent Health in 2025 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 81 increasing their positions, 65 reducing their positions, and 54 closing their positions.
215% more call options, than puts
Call options by funds: $3.04M | Put options by funds: $966K
25% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 65
7.45% less ownership
Funds ownership: 115.45% → 108% (-7.4%)
10% less funds holding
Funds holding: 240 → 215 (-25)
31% less first-time investments, than exits
New positions opened: 37 | Existing positions closed: 54
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
58% less capital invested
Capital invested by funds: $1.15B → $482M (-$666M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$15M |
| 2 |
D.E. Shaw & Co
New York
|
+$14.1M |
| 3 |
Jane Street
New York
|
+$8.4M |
| 4 |
TC
Tejara Capital
London,
United Kingdom
|
+$7.4M |
| 5 |
Morgan Stanley
New York
|
+$7.22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$53.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$48.6M |
| 3 |
William Blair Investment Management
Chicago,
Illinois
|
-$34.1M |
| 4 |
SAM
Silvercrest Asset Management
New York
|
-$15.2M |
| 5 |
8KM
8 Knots Management
Dallas,
Texas
|
-$15M |
EVH Hedge Fund Activity: Q4 2025 in Review
215 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Evolent Health (EVH) for Q4 2025, worth a combined $482M — down 58% from $1.15B a quarter earlier.
Sellers outnumbered buyers: 54 funds closed out of EVH and 37 opened new positions — a net loss of 17 holders — while 65 trimmed existing stakes and 81 added.
The largest buyer was UBS Group, adding an estimated $15M. The largest seller was Eventide Asset Management, exiting entirely with an estimated $53.2M sold.
- 215 institutional investors held Evolent Health (EVH) as of Q4 2025, down from 240 in Q3 2025.
- Funds reported $482M of Evolent Health stock for Q4 2025, down 58% quarter-over-quarter.
- 37 funds opened new Evolent Health positions in Q4 2025 and 54 closed out, a net change of -17 holders.
- The largest Evolent Health buyer in Q4 2025 was UBS Group, an estimated $15M added.
- The largest Evolent Health seller in Q4 2025 was Eventide Asset Management, an estimated $53.2M sold.
Based on aggregated 13F filings for Q4 2025.